Latest & greatest articles for breast cancer

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on breast cancer or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on breast cancer and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for breast cancer

1. Estrogen and Progesterone Receptor Testing in Breast Cancer

Estrogen and Progesterone Receptor Testing in Breast Cancer Estrogen and Progesterone Receptor Testing in Breast Cancer: ASCO/CAP Guideline Update | Journal of Clinical Oncology Search in: Menu Article Tools ASCO SPECIAL ARTICLES Article Tools OPTIONS & TOOLS COMPANION ARTICLES No companion articles ARTICLE CITATION DOI: 10.1200/JCO.19.02309 Journal of Clinical Oncology - published online before print January 13, 2020 PMID: Estrogen and Progesterone Receptor Testing in Breast Cancer: ASCO/CAP (...) ) testing in breast cancer guideline. METHODS A multidisciplinary international Expert Panel was convened to update the clinical practice guideline recommendations informed by a systematic review of the medical literature. RECOMMENDATIONS The Expert Panel continues to recommend ER testing of invasive breast cancers by validated immunohistochemistry as the standard for predicting which patients may benefit from endocrine therapy, and no other assays are recommended for this purpose. Breast cancer samples

2020 American Society of Clinical Oncology Guidelines

2. Estrogen and Progesterone Receptor Testing in Breast Cancer Guideline Update

Estrogen and Progesterone Receptor Testing in Breast Cancer Guideline Update EARLY ONLINE RELEASE Note: This article was posted on the Archives Web site as an Early Online Release. Early Online Release articles have been peer reviewed, copyedited, and reviewed by the authors. Additional changes or corrections may appear in these articles when they appear in a future print issue of the Archives. Early Online Release articles are citable by using the Digital Object Identifier (DOI), a unique (...) number given to every article. The DOI will typically appear at the end of the abstract. The DOI for this manuscript is doi: 10.5858/arpa.2019-0904-SA The fi nal published version of this manuscript will replace the Early Online Release version at the above DOI once it is available. © 3 College of American Pathologists 2020 Special Article Estrogen and Progesterone Receptor Testing in Breast Cancer American Society of Clinical Oncology/College of American Pathologists Guideline Update Kimberly H

2020 College of American Pathologists

3. Trastuzumab (Trazimera) - Breast Cancer or Gastric Cancer

Trastuzumab (Trazimera) - Breast Cancer or Gastric Cancer Search Page - Drug and Health Product Register Language selection Search and menus Search Search website Search Topics menu You are here: Summary Basis of Decision - - Health Canada Expand all Summary Basis of Decision (SBD) for Contact: Summary Basis of Decision (SBD) documents provide information related to the original authorization of a product. The for is located below. Recent Activity for SBDs written for approved after September 1

2020 Health Canada - Drug and Health Product Register

4. Neratinib maleate (Nerlynx) - adjuvant treatment of women with early-stage hormone receptor-positive, human epidermal growth factor receptor 2 (HER2)-overexpressed/amplified breast cancer

Neratinib maleate (Nerlynx) - adjuvant treatment of women with early-stage hormone receptor-positive, human epidermal growth factor receptor 2 (HER2)-overexpressed/amplified breast cancer Search Page - Drug and Health Product Register Language selection Search and menus Search Search website Search Topics menu You are here: Summary Basis of Decision - - Health Canada Expand all Summary Basis of Decision (SBD) for Contact: Summary Basis of Decision (SBD) documents provide information related

2020 Health Canada - Drug and Health Product Register

5. Talazoparib (Talzenna) - the treatment of adult patients with a deleterious or suspected deleterious germline breast cancer susceptibility gene (BRCA)-mutated human epidermal growth factor receptor 2 (HER2)-negative locally advanced (not amenable to curat

Talazoparib (Talzenna) - the treatment of adult patients with a deleterious or suspected deleterious germline breast cancer susceptibility gene (BRCA)-mutated human epidermal growth factor receptor 2 (HER2)-negative locally advanced (not amenable to curat Search Page - Drug and Health Product Register Language selection Search and menus Search Search website Search Topics menu You are here: Summary Basis of Decision - - Health Canada Expand all Summary Basis of Decision (SBD) for Contact

2020 Health Canada - Drug and Health Product Register

6. Cancer Screening: Interventions Engaging Community Health Workers – Breast Cancer

Cancer Screening: Interventions Engaging Community Health Workers – Breast Cancer Breast Cancer: Community Health Workers | The Community Guide Welcome to The Community Guide! Let us know what you think of the website by completing this . Open Navigation or Search form Search Search The Community Guide You are here » Systematic Review Topic Recommended (strong evidence) April 2019 Audience Adults Low-income Population Women Setting Clinical/Health Systems Community Home Strategy Health (...) Education Screening Cancer Screening: Interventions Engaging Community Health Workers – Breast Cancer Tabs Snapshot Summary of CPSTF Finding The interventions that engage community health workers to increase screening for breast cancer by mammography. Evidence shows these interventions increase breast cancer screening rates when community health workers deliver them independently or as part of an implementation team. Interventions that engage community health workers to increase breast cancer screening

2020 Community Preventive Services Task Force

7. Fam-trastuzumab deruxtecan-nxki (Enhertu) - metastatic breast cancer

Fam-trastuzumab deruxtecan-nxki (Enhertu) - metastatic breast cancer Drug Approval Package: ENHERTU ENHERTU " /> U.S. Department of Health and Human Services Search FDA Submit search Drug Approval Package: ENHERTU Company: Daiichi Sankyo, Inc. Application Number: 761139 Approval Date: 12/20/2019 Persons with disabilities having problems accessing the PDF files below may call (301) 796-3634 for assistance. FDA Approval Letter and Labeling (PDF) (PDF) FDA Application Review Files (PDF) (PDF) (PDF

2020 FDA - Drug Approval Package

8. Prognostic significance of receptor discordance between primary and recurrent breast cancer associated with survival in patients with breast cancer: a meta-analysis

Prognostic significance of receptor discordance between primary and recurrent breast cancer associated with survival in patients with breast cancer: a meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability

2020 PROSPERO

9. Optimal ovarian suppression duration for treatment of premenopausal patients with hormone receptor positive breast cancer: a meta-analysis and systematic review

Optimal ovarian suppression duration for treatment of premenopausal patients with hormone receptor positive breast cancer: a meta-analysis and systematic review Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content

2020 PROSPERO

10. Night shift work and risk of breast cancer: meta-analysis of case-control, cohort and nested case-control studies

Night shift work and risk of breast cancer: meta-analysis of case-control, cohort and nested case-control studies Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated

2020 PROSPERO

11. Linking physical activity to breast cancer: a two stage review of physical activity, sex steroid hormones, and breast cancer

Linking physical activity to breast cancer: a two stage review of physical activity, sex steroid hormones, and breast cancer Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any

2020 PROSPERO

12. Self-monitoring vs motivational interviewing: motivation techniques in self-directed physical activity to improve adherence in breast cancer survivors: a protocol for a systematic review and meta-analysis

Self-monitoring vs motivational interviewing: motivation techniques in self-directed physical activity to improve adherence in breast cancer survivors: a protocol for a systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears

2020 PROSPERO

13. Risk Factors and Outcomes During a First Acute Myocardial Infarction in Breast Cancer Survivors Compared with Females without Breast Cancer

Risk Factors and Outcomes During a First Acute Myocardial Infarction in Breast Cancer Survivors Compared with Females without Breast Cancer Risk Factors and Outcomes During a First Acute Myocardial Infarction in Breast Cancer Survivors Compared With Females Without Breast Cancer - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Welcome to the new PubMed. For legacy PubMed go to . Clipboard, Search History, and several other (...) characters Choose a collection: Unable to load your collection due to an error Add Cancel Add to My Bibliography My Bibliography Unable to load your delegates due to an error Add Cancel Actions Cite Share Permalink Copy Page navigation Am J Med Actions 2019 Nov 9 [Online ahead of print] Risk Factors and Outcomes During a First Acute Myocardial Infarction in Breast Cancer Survivors Compared With Females Without Breast Cancer , , , , , , , , , , Affiliations Expand Affiliations 1 Division of Cardiology. 2

2020 EvidenceUpdates

14. Palbociclib with fulvestrant for treating hormone receptor-positive, HER2-negative, advanced breast cancer

Palbociclib with fulvestrant for treating hormone receptor-positive, HER2-negative, advanced breast cancer Palbociclib with fulvestrant for treating hormone receptor-positive, HER2-negative, advanced breast cancer T echnology appraisal guidance Published: 15 January 2020 www.nice.org.uk/guidance/ta619 © NICE 2020. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-of- rights).Y Y our responsibility our responsibility The recommendations (...) and to reduce health inequalities. Commissioners and providers have a responsibility to promote an environmentally sustainable health and care system and should assess and reduce the environmental impact of implementing NICE recommendations wherever possible. Palbociclib with fulvestrant for treating hormone receptor-positive, HER2-negative, advanced breast cancer (TA619) © NICE 2020. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 2

2020 National Institute for Health and Clinical Excellence - Technology Appraisals

15. OWise mobile app and website for supporting women with breast cancer - Innovative Medical Technology Overview

OWise mobile app and website for supporting women with breast cancer - Innovative Medical Technology Overview IMTO | 1 IMTO 02-20 January 2020 OWise mobile app and website for supporting women with breast cancer Innovative Medical Technology Overview Key points ? OWise Breast Cancer is an app and website that offer a suite of tailored information and tools to support women with breast cancer. ? Included in the OWise app is information on disease pathology and care pathways, tailored questions (...) to prompt discussion with healthcare practitioners, an audio- recording function for use in consultations, a symptom tracker and an appointment diary. The ability to share patient symptom data in real-time with the NHSScotland TrakCare® patient record system is being evaluated in NHS Lothian. ? The OWise app is designed for use throughout the patient journey, in conjunction with standard treatments for breast cancer, as a replacement for paper-based support tools. ? There are currently no published

2020 SHTG Advice Statements

16. Role of intermittent pneumatic compression in the treatment of breast cancer-related lymphoedema: a randomized controlled trial

Role of intermittent pneumatic compression in the treatment of breast cancer-related lymphoedema: a randomized controlled trial Role of Intermittent Pneumatic Compression in the Treatment of Breast Cancer-Related Lymphoedema: A Randomized Controlled Trial - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Welcome to the new PubMed. For legacy PubMed go to . Clipboard, Search History, and several other advanced features (...) a collection: Unable to load your collection due to an error Add Cancel Add to My Bibliography My Bibliography Unable to load your delegates due to an error Add Cancel Actions Cite Share Permalink Copy Page navigation Clin Rehabil Actions , 269215519888792 2019 Dec 4 [Online ahead of print] Role of Intermittent Pneumatic Compression in the Treatment of Breast Cancer-Related Lymphoedema: A Randomized Controlled Trial , , , , , , Affiliations Expand Affiliations 1 Department of Physical Medicine

2020 EvidenceUpdates

17. Shared follow-up care for early breast cancer: summary of evidence

Shared follow-up care for early breast cancer: summary of evidence canceraustralia.gov.au 1 The need for new models of follow-up care for breast cancer Shared follow-up care for early breast cancer is an innovative model of care that supports the provision of holistic follow-up and survivorship care following active treatment. With high incidence and increasing survivorship following a diagnosis of breast cancer, progressively more people will require follow-up care, placing an increased demand (...) on Australia’s health system and resources. Shared care leverages the skills and expertise of the specialist and primary care workforce to support the delivery of high quality, safe and sustainable follow-up and survivorship care. Breast cancer will affect 1 in 7 people in Australia in their lifetime. It is estimated that 19,535 people will be diagnosed with the disease in Australia in 2019 (19,371 women and 164 men). 1 Australians experience some of the highest cancer survival rates in the world. 2,3 Breast

2020 Cancer Australia

18. Principles of shared follow-up care for early breast cancer

Principles of shared follow-up care for early breast cancer canceraustralia.gov.au Principles of shared follow-up care for early breast cancer SHARED FOLLOW-UP AND SURVIVORSHIP CARE FOR EARLY BREAST CANCER Cancer Australia’s seven Principles of shared follow-up care for early breast cancer are designed to underpin the delivery of shared follow-up and survivorship care for early breast cancer by health professionals and health services. Person-centred care The individual and their whole person (...) the provision of education, resources, information for people affected by cancer and pathways for access to specialist advice. Care is delivered according to best practice Provision of care is in accordance with nationally agreed standards and is outcome-focused. Individual follow-up care includes identified pathways for timely access to specialist providers as required. Support for the specialist treatment team The role of specialist care providers in the delivery of safe and effective follow-up care

2020 Cancer Australia

19. The effectiveness of interventions provided by breast cancer nurses: a systematic review

The effectiveness of interventions provided by breast cancer nurses: a systematic review Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites

2020 PROSPERO

20. The adverse effects of adjuvant hormone therapy regimes as an adjuvant therapy in breast cancer: a piggy-back systematic review and network meta-analysis

The adverse effects of adjuvant hormone therapy regimes as an adjuvant therapy in breast cancer: a piggy-back systematic review and network meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content

2020 PROSPERO